Clinical Trial Update: Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating rituximab with glofitamab and polatuzumab vedotin for previously untreated aggressive B-cell lymphoma ineligible for R-CHOP.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Columvi (glofitamab)
• Polivy (polatuzumab vedotin)
• Rituxan (rituximab)

Snippet

Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Conditions: Lymphoma, Large B-Cell, Diffuse | Phase 2 | Status: ACTIVE_NOT_RECRUITING